Euroapi’s near-term emissions targets have been validated by the Science Based Targets initiative, committing the European API and CDMO player to cut absolute scope 1 and 2 greenhouse gas emissions by 42% and scope 3 by 25% by 2030 from a 2022 baseline. The company reports early traction: from 2022 to 2024, it reduced waste by 28%, solvent consumption by 14%, and energy use by 12%, eliminated close to 180,000 tons of CO2e, shifted all purchased electricity to renewable sources, and made product carbon footprints available for more than 70 APIs.
The signal to the market is clear: emissions performance is no longer an ESG footnote for suppliers; it is a commercial credential. SBTi validation provides a standardized yardstick that many pharma procurement teams now expect, particularly as scope 3 emissions dominate corporate footprints and are increasingly pushed upstream. By quantifying and disclosing product-level footprints at the API stage, Euroapi is positioning decarbonization as a feature of the offer, not just a compliance obligation.
This matters now because environmental criteria are moving from soft commitments into hard gates in tenders and supplier scorecards. Health systems in Europe are integrating sustainability metrics into procurement, and large pharma sponsors are conditioning supplier selection on science-based targets and credible scope 3 plans. For brand and market access teams, a low-footprint API can become a differentiator in hospital tenders and a narrative element in payer dialogues, especially as sustainability weighting rises alongside price and supply reliability. For Medical Affairs, transparent product carbon data creates a foundation to support evidence packages that connect manufacturing choices to institutional sustainability goals without overreaching into clinical claims.
The stakes are competitive. European CDMOs are under price pressure from Asia while also absorbing EU environmental expectations, volatile energy markets, and looming disclosure rules. Demonstrable decarbonization progress can help defend share against low-cost imports if regulators and payers start valuing embedded carbon and supply-chain transparency more explicitly. It can also unlock sustainability-linked financing and qualify suppliers for preferred-vendor lists as pharma majors work toward their own net-zero commitments. Conversely, companies that lag on SBTi validation risk exclusion from RFP shortlists and face rising due diligence friction as customers seek to de-risk scope 3 exposure.
Execution will determine whether these targets translate into a durable advantage. Scope 3 reductions hinge on re-engineering chemistry steps, increasing process yields, switching to greener solvents, adopting continuous processing, and collaborating with solvent and logistics partners—areas that require joint planning with sponsors and potentially new contracting models. Product-level footprints for a subset of APIs are a promising start; extending that granularity across the portfolio and integrating digital emissions data into batch documentation could make sustainability auditable at the lot level, which is where procurement decisions are headed.
The strategic question now is whether decarbonization can shift from cost center to growth lever in the CDMO business. If health systems and pharma sponsors begin to reward lower embedded carbon with preferential tendering or long-term offtake, early movers like Euroapi may reset the basis of competition. Watch for sustainability-linked master service agreements, co-investment to redesign high-emission syntheses, and a widening gap between SBTi-validated suppliers and the rest as scope 3 expectations harden over the next RFP cycles.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
